OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
…
continue reading
1
The Auto Transplant Breast Cancer Scandal
15:28
15:28
Play later
Play later
Lists
Like
Liked
15:28
Did you know high-dose chemotherapy with autologous stem cel rescue was a "standard" breast cancer treatment ~30 years ago? This story involves changing practices based on Phase II data and outright clinical trial fraud, and retractions of publications.On-site review of Bezwoda study: https://doi.org/10.1016/S0140-6736(00)90024-2Oral History: https…
…
continue reading
Reflections from vacation on 1) How similar the chef training experience on The Bear mirrors some pharmacy residency training and 2) being a resource to family/friends with oncology questions.By John Bossaer
…
continue reading
Running through recent updates on epcoritamab, adagrasib + cetuximab for colorectal cancer, endometrial cancer, adjuvant dabrafenib/trametinib melanoma follow-up data, and topical capsaicin for delayed CINV.Also, a brief travelogue on my inaugural trip to ATOPP (advanced topics for oncology pharmacy professionals) Summit.…
…
continue reading
The MARIPOSA study suggests there may be a new preferred first line regimen (amivantamab + lazertinib) for metastatic EGFR-mutated NSCLC, as this regimen improved PFS compared to osimertinib.By John Bossaer
…
continue reading
An experimental regimen for DLBCL piques my interest.VenetoclaxibrutinibPrednisoneObinutuzumabRevlimid (lenalidomide)Link: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2401532By John Bossaer
…
continue reading
A new drug is approved for MDS. While some will likely benefit from this new agent, the more enticing news is that inhibiting telomerase may be an attractive target for many malignancies.By John Bossaer
…
continue reading
Lots and lots of updates from the past weekend's ASCO annual meeting.1. ADRIATIC (consolidation durvalumab in limited stage SCLC)2. NADINA (neoadjuvant Nivo/Ipi in stage III melanoma)3. *NICHE-2 (neoadjuvant Nivo/Ipi in dMMR colon cancer)4. CheckMate 8HW (Nivo/Ipi in dMMR metastatic colon cancer)5. TRANSMET (liver transplantation in colon cancer wi…
…
continue reading
1
Updated ASCO-ONS Antineoplastic Safety Standards
13:16
13:16
Play later
Play later
Lists
Like
Liked
13:16
ASCO & ONS (along with pharmacist representation) released updated safety standards for preparing, administering, and monitoring chemotherapy. Look for a calendar invitation to review your site's policies soon.Link: https://doi.org/10.1200/OP.24.00216By John Bossaer
…
continue reading
A new drug for small-cell lung cancer, a bispecific, targeting DLL3 on small-cell lung cancer and CD3 on T-cells is FDA approved. But, infigratinib's FDA approval for cholangiocarcinoma is withdrawn.By John Bossaer
…
continue reading
QT interval prolongation is a common hurdle to taking care of cancer patients. We dive into what QT interval prolongation is, why it matters, risk factors, and prevention/management strategies.By John Bossaer
…
continue reading
The non-Award Winning series of Landmarks in OncoPharm returns to discuss a Next Big Thing in NHL that wasn't any better than plain old CHOP.From April 1993, it's Pro-MACE-CytaBOMLink: https://www.nejm.org/doi/full/10.1056/NEJM199304083281404By John Bossaer
…
continue reading
1
Tisotumab Vedotin, HD Mtx In CNS Lymphoma & Class III BRAF Mutations
9:37
9:37
Play later
Play later
Lists
Like
Liked
9:37
Tisotumab vedotin garners a regular FDA approval for metastatic cervical cancer with OS benefit data.A lingering question that demands a focused RCT: What is the optimal dose of methotrexate in primary CNS lymphoma? I'm glad I'm not the only one with this question: https://doi.org/10.1177/10781552231176754What, some BRAF mutations in colorectal can…
…
continue reading
Lots of recent updates to cover this week...1. Adjuvant pembrolizumab of RCC demonstrates OS improvement in NEJM publication (DOI: 10.1056/NEJMoa2312695)2. Yet adjuvant nivolumab did not demonstrate OS improvement in the adjuvant setting. There may be a few reasons for this (https://doi.org/10.1200/JCO.2024.42.4_suppl.LBA358)3. A cytokine-fusion pr…
…
continue reading
Arguably, the most anticipated release of 4/19/24By John Bossaer
…
continue reading
What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma.Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors.Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this we…
…
continue reading
Tumor Lysis Syndrome (TLS) is a foundational topic for all oncology clinicians. We discuss the what, the why, prevention, and treatment.By John Bossaer
…
continue reading
1
Updates In RCC, Pancreatic Cancer, And Skin Cancer In SOT
13:44
13:44
Play later
Play later
Lists
Like
Liked
13:44
Discussing four papers that caught our eyes from the last few weeks:Pazopanib vs. placebo following metastatectomy. Always concerning when placebo has an OS advantage.ECOG-ACRIN E2810: https://doi.org/10.1200/JCO.23.01544Gemcitabine vs. Gem + Paclitaxel (Taxol) in pancreatic cancer patients after FOLFIRINOX: https://doi.org/10.1200/JCO.23.00795An R…
…
continue reading
Two recent publications suggest more people may be choosing non-colonoscopy screening practices in the future. One is a new stool DNA test, while the other is a blood test.How do they compare to the gold standard of colonoscopy?Cell-free DNA blood test: DOI: 10.1056/NEJMoa2304714Next generation stool DNA test: DOI: 10.1056/NEJMoa2310336…
…
continue reading
EV-302 is finally published, and you have to squint to find any major critiques. Enfortumab bedouin + pembrolizumab fully arrives as a standard 1st-line regimen of advanced urothelial cancer.Also, nivolumab gets a 1st-line FDA approval for urothelial carcinoma in conjunction with cisplatin + gemcitabine based on CHECKMATE-901.…
…
continue reading
Two nice studies have been recently published in the supportive care realm.SPARED asks if we can omit dexamethasone on days 2-4 following cisplatin-based chemotherapy.D-TORCH asks if topical diclofenac can prevent capecitabine-induced hand-foot syndrome.SPARED: https://doi.org/10.1038/s41416-023-02493-7 D-TORCH: https://doi.org/10.1200/JCO.23.01730…
…
continue reading
An exciting new cellular therapy, lifileucel, is approved for metastatic melanoma. The FLAURA2 trial of osimertinib + chemotherapy has led to an FDA approval, but questions remain about a possible new standard of care. And a few minor updates on tepotinib.By John Bossaer
…
continue reading
1
NAPOLI 3, POUT, & Ivosidenib - Azole DDIs
15:19
15:19
Play later
Play later
Lists
Like
Liked
15:19
New updates on metastatic pancreatic cancer (NAPOLI-3), upper tract urothelial cancer (POUT), and the drug-drug interaction between ivosidenib and azole antifungals.NAPOLI 3: https://doi.org/10.1016/S0140-6736(23)01366-1POUT (final OS): https://doi.org/10.1200/JCO.23.01659Ivosidenib Azole Antifungal DDIs: https://doi.org/10.1002/cncr.35251…
…
continue reading
You know about small cell lung cancer, but let's talk about small cell carcinoma of the prostate.By John Bossaer
…
continue reading
1
Rethinking Some Fundamental Considerations
15:41
15:41
Play later
Play later
Lists
Like
Liked
15:41
In oncology we are always asking questions about which treatment option is best. And that focus on the next best treatment may prevent us from rethinking some fundamentals of current practice. Three recent studies illustrate this and made me ask:Do we need a Port or PICC for every testicular cancer patient?Study: https://doi.org/10.1200/OP.23.00580…
…
continue reading
...on FDA approvals for belzutifan for RCC, pembrolizumab + cisplatin/RT for cervical cancer, erdafitinib (FGFR3 alterations only) for bladder cancer.Plus, early morning ICIs (https://doi.org/10.1016/j.ejca.2024.113571)&FLAG-Ida-GO in AML from NCRI AML 19 (https://doi.org/10.1200/JCO.23.00943)By John Bossaer
…
continue reading
1
Development Of Generic Lenalidomide with Dr. Ryan Beechinor
34:39
34:39
Play later
Play later
Lists
Like
Liked
34:39
Special guest Ryan Beechinor joins the pod to discuss his recent paper on the obstacles in the development of generic lenalidomide. It's a fantastic read, and this episode will be a fantastic listen!Link: https://doi.org/10.1016/j.jcpo.2023.100446By John Bossaer
…
continue reading
Foundations of OncoPharm episode on lenalidomide (Revlimid) and its MOA, use, dosing, & toxicity.By John Bossaer
…
continue reading
A Holiday Tradition returns as we review 14 new OncoPharm drugs approved this past year and ask Keep, Re-Gift, or Return.By John Bossaer
…
continue reading
Small bites of updates coming out of ASH's 2023 annual meeting on CLL, multiple myeloma, and lymphoma.By John Bossaer
…
continue reading
Our Landmarks of OncoPharm series returns to talk about 2008's VISTA study, which ushered bortezomib into the front line setting, albeit with a now outdated alkylating agent-based backbone.VISTA (VMP vs. MP): https://www.nejm.org/doi/full/10.1056/nejmoa0801479By John Bossaer
…
continue reading
The recent approval of nirogacestat, the first gamma secretase inhibitor on the market, provides a great opportunity to discuss desmoid tumors and Notch signaling.Review article: https://doi.org/10.1002/onco.13627Also, a new T-cell malignancy warning for most CAR-T products. And, is belantamab mafodotin coming back based on the DREAMM-7 results?…
…
continue reading
FDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.By John Bossaer
…
continue reading
1
Fruquintinib And Osimertinib-Chemo in Combo?
16:58
16:58
Play later
Play later
Lists
Like
Liked
16:58
This week's Pod dives into a new VEGF-R inhibitor, fruquintinib. We also ask if FLAURA2, osimertinib + chemotherapy in combination, will become a new standard of care in EGFR-mutated metastatic NSCLC.By John Bossaer
…
continue reading
Aggressive hematologic malignancy publications can be challenging to interpret and translate to clinical practice.We look at two recent studies to illustrate this point. Elderly AML: 10-day decitabine vs. 7 + 3 (https://doi.org/10.1016/S2352-3026(23)00273-9)Burkitt Lymphoma: R-CODXO-M/R-IVAC vs. DA-R-EPOCH (https://doi.org/10.1016/S2352-3026(23)002…
…
continue reading
Out Landmarks of OncoPharm series returns to chronicle how treatment of stage III NSCLC has changed over time with an overview of three studies.1. Dillman (1990) NEJM (sequential chemo --> RT): https://doi.org/10.1056/nejm1990100432314032. Albain (1995) JCO (concurrent cisplatin/etoposide + RT): https://pubmed.ncbi.nlm.nih.gov/?term=76365303. Albai…
…
continue reading
Lots of practice changing new information came out of last week's ESMO conference.This Pod is packed with updates on NSCLC, bladder cancer, gastric cancer, medullary thyroid cancer, KRAS G12C colorectal cancer.....and even bendamustine (non-ESMO update).By John Bossaer
…
continue reading
1
Enzalutamide monotherapy? Plus, nivolumab & pembrolizumab approval updates
17:05
17:05
Play later
Play later
Lists
Like
Liked
17:05
This week we discuss the continued push to introduce 2nd generation androgen inhibitors earlier into treatment with the EMBARK trial.Nivolumab and pembrolizumab, pemrolizumab and nivolumab. Again and again. Their role (and approvals) for adjuvant melanoma make sense. But what to think about their use for NSCLC in the neoadjuvant setting?West commen…
…
continue reading
Encorafenib + binimetinib gets FDA-approval for metastatic NSCLC, but how does it compare to dabrafenib/trametinib? Plus, a new pediatric approval for dabrafenib/trametinib means more dosage form options.By John Bossaer
…
continue reading
Trying to make sense of the limited information put out via Press Release the last 2 weeks for mobocertinib, pembrolizumab + enfortumab vedotin, nivolumab, and more.By John Bossaer
…
continue reading
From the Foundations of OncoPharm archives - the history and groundbreaking STI 571 (imatinib).By John Bossaer
…
continue reading
It's another Landmarks of OncoPharm episode looking at the carboplatin-paclitaxel regimen in ovarian cancer from 20 years ago.carboplatin/paclitaxel vs. cisplatin/paclitaxel: https://pubmed.ncbi.nlm.nih.gov/?term=37643542By John Bossaer
…
continue reading
An experimental drug for EGFRm NSCLC, patritumab deruxtecan (HER3-DXd), raises some eyebrows and a new agent is FDA-approved for hematopoietic stem cell mobilization (motixafortide).By John Bossaer
…
continue reading
You read it in every solid tumor paper - RECIST - criteria. This Pod discusses some of the details of the Response Evaluation in Solid Tumors (RECIST) criteria along with the pros and cons of its use - including a modification of the criteria for use with immunotherapy.By John Bossaer
…
continue reading
1
DPYD Variant Dosing & ICIs In Pancreatic Cancer
19:33
19:33
Play later
Play later
Lists
Like
Liked
19:33
Empiric dose reductions for variant DPYD alleles isn't necessarily new, but the outcomes of patients treated with those dose reductions isn't well described. Dutch researchers provide some much needed evidence.Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh ma…
…
continue reading
A Foundations of OncoPharm episode on nab-paclitaxel, with a focus on the pharmaceutical differences from conventional paclitaxel.By John Bossaer
…
continue reading
1
Niraparib + Abiraterone, Elranatamab, & Melphalan Updates
14:25
14:25
Play later
Play later
Lists
Like
Liked
14:25
A combination product is now available of niraparib + abiraterone for use in mCRPC. Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.By John Bossaer
…
continue reading
Talquetamab is approved for r/r multiple myeloma and the STOP-CA trials asks if atorvastatin can prevent anthracycline cardiotoxicity.STOP-CA: https://jamanetwork.com/journals/jama/fullarticle/2807988By John Bossaer
…
continue reading
The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients.Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.By John Bossaer
…
continue reading
By listener request! What is BCOP, why pursue it, and some simple tips on studying for the exam.By John Bossaer
…
continue reading
1
Chemotherapy Sequencing In Colorectal Cancer
13:36
13:36
Play later
Play later
Lists
Like
Liked
13:36
A Landmark of OncoPharm from 2004: FOLFIRI --> FOLFOX or FOLFOX --> FOLFIRI.Some interesting dosing to discuss in this study.Link: https://pubmed.ncbi.nlm.nih.gov/?term=37379692By John Bossaer
…
continue reading